Commonly used nonionic surfactants interact differently with the human efflux transporters ABCB1 (p-glycoprotein) and ABCC2 (MRP2).
暂无分享,去创建一个
Werner Weitschies | Werner Siegmund | W. Weitschies | S. Nagel | Karen May | W. Siegmund | Ulrike Hanke | Veronika Rozehnal | Stefan Nagel | K. May | U. Hanke | Veronika Rozehnal | Ulrike Hanke
[1] K. Lyons,et al. Utility of unbound plasma drug levels and P-glycoprotein transport data in prediction of central nervous system exposure , 2009, Xenobiotica; the fate of foreign compounds in biological systems.
[2] A. Kabanov,et al. Effect of Pluronic P85 on ATPase Activity of Drug Efflux Transporters , 2004, Pharmaceutical Research.
[3] D. Aggarwal,et al. Paclitaxel and its formulations. , 2002, International journal of pharmaceutics.
[4] M. Schleimer,et al. Potential inhibitory effects of formulation ingredients on intestinal cytochrome P450. , 2000, International journal of pharmaceutics.
[5] G. Fricker,et al. Xenobiotic efflux pumps in isolated fish brain capillaries. , 2002, American journal of physiology. Regulatory, integrative and comparative physiology.
[6] P. Artursson,et al. Epithelial transport of drugs in cell culture. I: A model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells. , 1990, Journal of pharmaceutical sciences.
[7] B. Hirst,et al. Intestinal secretion of drugs. The role of P-glycoprotein and related drug efflux systems in limiting oral drug absorption , 1997 .
[8] P. Twentyman,et al. On the relationship between the probenecid‐sensitive transport of daunorubicin or calcein and the glutathione status of cells overexpressing the multidrug resistance‐associated protein (MRP) , 1995, International journal of cancer.
[9] D. Stevens,et al. Effect of cyclodextrin on the pharmacology of antifungal oral azoles , 1992, Antimicrobial Agents and Chemotherapy.
[10] Yuichi Sugiyama,et al. Comparative Studies on in Vitro Methods for Evaluating in Vivo Function of MDR1 P-Glycoprotein , 2001, Pharmaceutical Research.
[11] W. Hauck,et al. Interpatient variability in bioavailability is related to the extent of absorption: Implications for bioavailability and bioequivalence studies , 1996, Clinical pharmacology and therapeutics.
[12] Gerd Mikus,et al. Pharmacokinetic and pharmaceutic interaction between digoxin and Cremophor RH40 , 2003, Clinical pharmacology and therapeutics.
[13] D. Hallifax,et al. Predicting P-Glycoprotein Effects on Oral Absorption: Correlation of Transport in Caco-2 with Drug Pharmacokinetics in Wild-Type and mdr1a(-/-) Mice in Vivo , 2004, Pharmaceutical Research.
[14] T. Zoeller,et al. Improving glyburide solubility and dissolution by complexation with hydroxybutenyl‐β‐cyclodextrin , 2009 .
[15] D. Schrenk,et al. Evaluation of a vincristine resistant Caco-2 cell line for use in a calcein AM extrusion screening assay for P-glycoprotein interaction. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[16] J. Schellens,et al. Evidence for Two Interacting Ligand Binding Sites in Human Multidrug Resistance Protein 2 (ATP Binding Cassette C2)* , 2003, Journal of Biological Chemistry.
[17] B. Tran,et al. Probenecid reverses multidrug resistance in multidrug resistance-associated protein-overexpressing HL60/AR and H69/AR cells but not in P-glycoprotein-overexpressing HL60/Tax and P388/ADR cells , 1997, Cancer Chemotherapy and Pharmacology.
[18] B. Hirst,et al. The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. , 2004, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[19] M C Willingham,et al. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[20] M. Kool,et al. Inhibitory effect of the reversal agents V-104, GF120918 and Pluronic L61 on MDR1 Pgp-, MRP1- and MRP2-mediated transport , 2000, British Journal of Cancer.
[21] R L Juliano,et al. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. , 1976, Biochimica et biophysica acta.
[22] C. Higgins,et al. ABC transporters: from microorganisms to man. , 1992, Annual review of cell biology.
[23] M. Wempe,et al. Influence of vitamin E TPGS poly(ethylene glycol) chain length on apical efflux transporters in Caco-2 cell monolayers. , 2006, Journal of controlled release : official journal of the Controlled Release Society.
[24] B. Williams,et al. Reversal of the multidrug resistance phenotype with cremophor EL, a common vehicle for water-insoluble vitamins and drugs. , 1990, Cancer research.
[25] K. Anderson,et al. Reversal of multidrug resistance phenotype by surfactants: relationship to membrane lipid fluidity. , 1995, Archives of biochemistry and biophysics.
[26] M. Gottesman,et al. Targeting multidrug resistance in cancer , 2006, Nature Reviews Drug Discovery.
[27] B. Aungst,et al. Intestinal permeation enhancers. , 2000, Journal of pharmaceutical sciences.
[28] J. Huwyler,et al. Improved oral bioavailability of cyclosporin A in male Wistar rats. Comparison of a Solutol HS 15 containing self-dispersing formulation and a microsuspension. , 2002, International journal of pharmaceutics.
[29] M. Kool,et al. Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. , 1998, The Journal of clinical investigation.
[30] Alexander V Kabanov,et al. Optimal Structure Requirements for Pluronic Block Copolymers in Modifying P-glycoprotein Drug Efflux Transporter Activity in Bovine Brain Microvessel Endothelial Cells , 2003, Journal of Pharmacology and Experimental Therapeutics.
[31] F. Russel,et al. Impaired renal secretion of substrates for the multidrug resistance protein 2 in mutant transport-deficient (TR-) rats. , 2003, Journal of the American Society of Nephrology : JASN.
[32] P. Bosma,et al. Congenital Jaundice in Rats with a Mutation in a Multidrug Resistance-Associated Protein Gene , 1996, Science.
[33] C. Klaassen,et al. Organ distribution of multidrug resistance proteins 1, 2, and 3 (Mrp1, 2, and 3) mRNA and hepatic induction of Mrp3 by constitutive androstane receptor activators in rats. , 2002, The Journal of pharmacology and experimental therapeutics.
[34] D. Keppler,et al. The rat canalicular conjugate export pump (Mrp2) is down-regulated in intrahepatic and obstructive cholestasis. , 1997, Gastroenterology.
[35] Yuichi Sugiyama,et al. Improvement of the Oral Drug Absorption of Topotecan through the Inhibition of Intestinal Xenobiotic Efflux Transporter, Breast Cancer Resistance Protein, by Excipients , 2007, Drug Metabolism and Disposition.
[36] R. Borchardt,et al. The Use of Surfactants to Enhance the Permeability of Peptides Through Caco-2 Cells by Inhibition of an Apically Polarized Efflux System , 1996, Pharmaceutical Research.
[37] I. Wilson,et al. Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. , 2000, European journal of biochemistry.
[38] Akira Yamamoto,et al. Modulation of intestinal P-glycoprotein function by cremophor EL and other surfactants by an in vitro diffusion chamber method using the isolated rat intestinal membranes. , 2004, Journal of pharmaceutical sciences.
[39] P. Borst,et al. Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. , 1995, The Journal of clinical investigation.
[40] James E Polli,et al. Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers. , 2002, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[41] N. Shaik,et al. Investigation of the micellar effect of pluronic P85 on P-glycoprotein inhibition: cell accumulation and equilibrium dialysis studies. , 2009, Journal of Pharmacy and Science.
[42] Donald W. Miller,et al. Sensitization of Cells Overexpressing Multidrug-Resistant Proteins by Pluronic P85 , 2003, Pharmaceutical Research.
[43] D. Häussinger,et al. Regulation of the multidrug resistance protein 2 in the rat liver by lipopolysaccharide and dexamethasone. , 1999, Gastroenterology.
[44] Jochem Alsenz,et al. The role of surfactants in the reversal of active transport mediated by multidrug resistance proteins. , 2003, Journal of pharmaceutical sciences.
[45] G. Fricker,et al. Relevance of multidrug resistance proteins for intestinal drug absorption in vitro and in vivo. , 2002, Pharmacology & toxicology.
[46] J. Verweij,et al. Rapid esterase-sensitive breakdown of polysorbate 80 and its impact on the plasma pharmacokinetics of docetaxel and metabolites in mice. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[47] A. Collett,et al. Investigation of Regional Mechanisms Responsible for Poor Oral Absorption in Humans of a Modified Release Preparation of the α-Adrenoreceptor Antagonist, 4-Amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4 tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline (UK-338,003): The Rational Use of ex Vivo , 2008, Drug Metabolism and Disposition.